Research presented by Professor Nigel Bundred at the European Breast Cancer Conference in Amsterdam revealed that they had tested the effectiveness of a pair of drugs known as Herceptin (a.k.a trastuzumab) and Lapatinib. The two drugs are commonly used in breast cancer treatment already, but this is the first time they had been combined together and used before surgery and chemotherapy. They were able to eliminate some types of breast cancer in just 11 days.
Funded by Cancer Research UK, they aimed to use these drugs to combat a protein called HER2 (human epidermal growth factor receptor 2), which affects the growth and division of cancer cells. It’s also more likely to return than other cancer types.
What also makes this treatment so appealing is the fact that it may eliminate the need for chemotherapy and/or surgery in some cases.